Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CollPlant Biotechnologies's gross profit for the
three
months ended in Mar. 2026 was €-0.21 Mil. CollPlant Biotechnologies's gross profit for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.49 Mil.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
CollPlant Biotechnologies had a gross margin of -333.33% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
CollPlant Biotechnologies Gross Profit Related Terms
CollPlant Biotechnologies Gross Profit Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:CPT vs DRMA, AAGH, HCWB: Gross Profit Comparison
For the Biotechnology subindustry, CollPlant Biotechnologies's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CollPlant Biotechnologies Gross Profit vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CollPlant Biotechnologies's Gross Profit distribution charts can be found below:
* The bar in red indicates where CollPlant Biotechnologies's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.49 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
CollPlant Biotechnologies (FRA:CPT) has a Gross Profit of €-0.49 Mil as of Mar. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on CollPlant Biotechnologies and its competitors.
Is CollPlant Biotechnologies' Gross Profit too high?
CollPlant Biotechnologies' current Gross Profit is €-0.49 Mil. Overall, CollPlant Biotechnologies has a GF Score™ of 47/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CollPlant Biotechnologies' Gross Profit compare to DRMA and AAGH?
CollPlant Biotechnologies' Gross Profit of €-0.49 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Biotechnology company?
A good Gross Profit depends on the Biotechnology industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on CollPlant Biotechnologies and its competitors. CollPlant Biotechnologies's current Gross Profit is €-0.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CollPlant Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, CollPlant Biotechnologies (FRA:CPT) is currently considered Modestly Overvalued. The stock's GF Value™ is €2.35, compared to a current price of €2.94 — trading 25.1% above its estimated fair value. The current Gross Profit is €-0.49 Mil. CollPlant Biotechnologies' overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For CollPlant Biotechnologies (FRA:CPT), the current Gross Profit is €-0.49 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CollPlant Biotechnologies (FRA:CPT) Overvalued in 2026?
Based on GuruFocus' analysis, CollPlant Biotechnologies stock appears to be overvalued.
The current stock price of €2.94 is trading 25.1% above its estimated GF Value™ of €2.35.
GuruFocus considers CollPlant Biotechnologies to be Modestly Overvalued.
Key valuation signals for FRA:CPT:
Gross Profit: €-0.49 Mil
GF Value™: €2.35 vs. price of €2.94 (25.1% above fair value)
No single metric tells the full story. See the FRA:CPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.
47GF Score
Get the complete analysis for FRA:CPT
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:CPT has been successfully added to your 
